Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems

BMC Infectious Diseases

Volumn 16, Issue 1, 2016, Pages

  Fukuchi, Takahiko ^a   Iwata, Kentaro ^a   Kobayashi, Saori ^b   Nakamura, Tatsuya ^b   Ohji, Goh ^a,b  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY HOSPITAL   (Japan)

Author keywords

Bacteremia; Cefmetazole; Cephamycin; ESBL; Extended spectrum beta lactamase

Indexed keywords

BIAPENEM; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEFEPIME; CEFMETAZOLE; CEFOPERAZONE PLUS SULBACTAM; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; DORIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAMASE;

AGED; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CTX M 9 GENE; DRUG SAFETY; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING KLEBSIELLA PNEUMONIAE; FEMALE; GENE IDENTIFICATION; HEPATOBILIARY SYSTEM INFECTION; HUMAN; KLEBSIELLA OXYTOCA; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; URINARY TRACT INFECTION; ANTIBIOTIC RESISTANCE; BACTEREMIA; ENTEROBACTERIACEAE; ENZYMOLOGY; ISOLATION AND PURIFICATION; KLEBSIELLA PNEUMONIAE; METABOLISM; MICROBIOLOGY; MIDDLE AGED; URINARY TRACT INFECTIONS;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; CARBAPENEMS; CEFMETAZOLE; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ESCHERICHIA COLI; FEMALE; HUMANS; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; URINARY TRACT INFECTIONS;

EID: 84982234731     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-016-1770-1     Document Type: Article

References (21)

1. Signs V. Carbapenem-Reistant Enterobacteriaceae. MMWR. 2013;62:165-70.
2. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012;67(12):2793-803.
3. Force TBART. The Cost of Antibiotic Resistance: Effect of Resistance Among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa on Length of Hospital Stay. Infection Control and Hospital Epideimology. 2002;23:106-8.
4. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007;60(5):913-20.
5. Leistner R, Gurntke S, Sakellariou C, Denkel LA, Bloch A, Gastmeier P, et al. Bloodstream infection due to extended-spectrum beta-lactamase (ESBL)-positive K. pneumoniae and E. coli: an analysis of the disease burden in a large cohort. Infection. 2014;42(6):991-7.
6. Paterson D. Antibiotic Therapy for Klebsiella pneumoniae Bacteremia: Implications of Production of Extended-Spectrum B-Lactamase. Clin Infect Dis. 2003;39:31-7.
7. Marchaim D, Chopra T, Bhargava A, Bogan C, Dhar S, Hayakawa K, et al. Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship. Infect Control Hosp Epidemiol. 2012;33(8):817-30.
8. Tumbarello M, Spanu T, Di Bidino R, Marchetti M, Ruggeri M, Trecarichi EM, et al. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother. 2010;54(10):4085-91.
9. Falagas ME, Karageorgopoulos DE. Extended-spectrum beta-lactamase-producing organisms. J Hosp Infect. 2009;73(4):345-54.
10. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657-86.
11. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis. 1988;10:867-78.
12. Kumar A. Optimizing antimicrobial therapy in sepsis and septic shock. Crit Care Clin. 2009;25:733-51.
13. Matsumura Y, Yamamoto M, Nagao M, Komori T, Fujita N, Hayashi A, et al. Multicenter Retrospective Study of Cefmetazole and Flomoxef for Treatment of Extended-Spectrum-beta-Lactamase-Producing Escherichia coli Bacteremia. Antimicrob Agents Chemother. 2015;59(9):5107-13.
14. Doi A, Shimada T, Harada S, Iwata K, Kamiya T. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Int J Infect Dis. 2013;17(3):e159-63.
15. Tsai HY, Chen YH, Tang HJ, Huang CC, Liao CH, Chu FY, et al. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Proteus mirabilis. Diagn Microbiol Infect Dis. 2014;80(3):222-6.
16. Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia. Clin Infect Dis. 2015;60(9):1319-25.
17. Fong JJ, Rosé L, Radigan EA. Clinical outcomes with ertapenem as a first-line treatment option of infections caused by extended-spectrum β-lactamase producing gram-negative bacteria. Ann Pharmacother. 2012;46(3):347-52.
18. Lim C. Evaluation of Ertapenem use with Impact Assessment on Extended-Spectrum Beta-Lactamase (ESBL) Production and Gram-Negative resistance in Singapore General Hospital (SGH). BMC Infectious Disease. 2013;13:523.
19. Kang CI, Cha MK, Kim SH, Ko KS, Wi YM, Chung DR, et al. Clinical and molecular epidemiology of community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli over a 6-year period. J Korean Med Sci. 2013;28(7):998-1004.
20. Park SH, Choi SM, Chang YK, Lee DG, Cho SY, Lee HJ, et al. The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum beta-lactamase-producing Escherichia coli. J Antimicrob Chemother. 2014;69(10):2848-56.
21. Chung HC, Lai CH, Lin JN, Huang CK, Liang SH, Chen WF, et al. Bacteremia caused by extended-spectrum-beta-lactamase-producing Escherichia coli sequence type ST131 and non-ST131 clones: comparison of demographic data, clinical features, and mortality. Antimicrob Agents Chemother. 2012;56(2):618-22.